Company Summary
Based in Franklin Lakes, NJ, Becton, Dickinson and Company, commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents.
BD’s operations consist of three business segments: BD Medical, BD Life Sciences and BD Interventional.
In fiscal 2023, BD’s revenues increased 2.7% to $19.37 billion.
BD Medical (49.1% of fiscal 2023 revenues, up 7.5% from FY22): BD Medical produces a broad array of medical technologies and devices to help improve healthcare delivery in a wide range of settings. The primary customers served by BD Medical are hospitals and clinics and pharmaceutical companies, among others.
BD Life Sciences (26.5%, down 7.8%): BD Life Sciences provides products for the safe collection and transport of diagnostics specimens, instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. The segment also produces research and clinical tools that facilitate the study of cells and the components of cells to gain a better understanding of normal and disease processes. The primary customers served by BD Life Sciences are hospitals, laboratories and clinics and pharmaceutical and biotechnology companies, among others. With the emergency use authorization approval of the At Home COVID-19 test, BD Life Sciences also serves patients directly.
BD Interventional (24.4%, up 6.1%): BD Interventional provides vascular, urology, oncology and surgical specialty products that are intended to be used once and then discarded or are either temporarily or permanently implanted. The primary customers served by BD Interventional are hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities and patients via BD’s Homecare business.